Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec;13(6):3135–3153. doi: 10.21037/jgo-22-1101

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Journal of Gastrointestinal Oncology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The performance of the IMScore model in the patients treated with immunotherapy. (A) Survival curve and ROC curve analysis of IMScore performance in IMvigor210 dataset. (B) Survival curve and ROC curve analysis of TIDE score performance in IMvigor210 dataset. (C) Survival curve and ROC curve analysis of IMScore performance in GSE91061 dataset. (D) Survival curve and ROC curve analysis of TIDE score performance in GSE91061 dataset. (E,F) The AUC of predicting the response to immunotherapy in IMvigor210 (E) and GSE91061 (F) datasets. ROC, receiver operating characteristic; TIDE, Tumor Immune Dysfunction and Exclusion; AUC, area under the curve.